Wuhan Hiteck Biological Pharma Co Ltd
300683
Company Profile
Business description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Contact
Hite Science and Technology Park
Wuhan Economic and Technological Development Zone
Hubei Province
Wuhan430056
CHNT: +86 2784599931
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,309
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.00 | 0.50 | 0.01% |
| CAC 40 | 7,895.94 | 15.07 | 0.19% |
| DAX 40 | 23,880.72 | 135.66 | 0.57% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,350.43 | 50.59 | 0.54% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,544.19 | 388.44 | -0.86% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 27.25 | 0.41% |
| S&P/ASX 200 | 8,831.20 | 2.20 | -0.02% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |